Digitisation | November 14, 2023
BioPhy launches AI platform to accelerate the drug development market
The company has raised US$4.5 million in funding for its AI operating system
The company has raised US$4.5 million in funding for its AI operating system
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
The companies plan to start a pivotal Phase 3 trial in the coming months
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity
Biosergen AB is developing BSG005 for the treatment of severe and difficult-to-treat invasive fungal diseases
The companies will work with investigators to share the results with the scientific community
Opinion granted based on positive disease-free survival results from the Phase 3 KEYNOTE-091 trial
Brian Foard will lead the Specialty Care GBU ad interim, effective immediately.
Subscribe To Our Newsletter & Stay Updated
